Lupin Partners With SteinCares To Supply Biosimilar in LATAM
ECONOMY & POLICY

Lupin Partners With SteinCares To Supply Biosimilar in LATAM

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.

As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.

Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).

Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”

Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”

This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Global pharmaceutical major Lupin Limited has entered into a licence and supply agreement with SteinCares, a leading Latin American speciality healthcare firm, for the commercialisation of Lupin’s biosimilar ranibizumab across Latin America, excluding Mexico and Argentina.As per the agreement, SteinCares will manage all regulatory submissions, registrations, and commercial activities, while Lupin will be responsible for manufacturing the biosimilar.Ranibizumab is a recombinant humanised monoclonal antibody fragment (IgG1) that targets and inhibits vascular endothelial growth factor A (VEGF-A). It is used to treat several retinal conditions including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Oedema following Retinal Vein Occlusion (RVO), Diabetic Macular Oedema (DME), Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularisation (mCNV).Dr Cyrus Karkaria, President of Biotechnology at Lupin, said, “This partnership underscores our commitment to making advanced retinal therapies accessible in Latin America and improving patients’ quality of life.”Sebastián Katz, Chief Strategy Officer at SteinCares, added, “Our collaboration with Lupin bolsters our leadership in the biosimilar space and helps bring affordable, high-quality treatments to healthcare systems across the region.”This partnership aims to enhance the reach of cost-effective, advanced ophthalmic treatments across Latin America, aligning with both companies’ missions to deliver impactful healthcare solutions.

Next Story
Building Material

Suraj Estate Wins Euromoney Award for India’s Best Residential Developer

"Suraj Estate Developers Limited has received the Euromoney Real Estate Award 2025 for ‘India’s Best Residential Developer’, positioning the company among globally benchmarked leaders in the sector. The recognition reflects its four-decade legacy in delivering high-quality residential and redevelopment-led projects across South Central Mumbai. The Euromoney Real Estate Awards, presented by the London-based Euromoney magazine, are widely regarded as one of the most credible global assessments of performance in real estate, banking and finance. Winners are selected through surveys of inte..

Next Story
Building Material

Lloyds Metals, Tata Steel Sign MoU to Explore Strategic Collaboration

"Lloyds Metals and Energy Limited has signed a non-binding Memorandum of Understanding with Tata Steel Limited to evaluate potential areas of strategic cooperation across mining, logistics, pelletisation and steelmaking. The MoU was signed by B Prabhakaran, Managing Director of Lloyds Metals, and Mr T V Narendran, CEO and Managing Director of Tata Steel. The partnership framework aims to leverage the natural operational synergies between both companies and assess opportunities in greenfield steel projects, iron ore mining, slurry pipeline infrastructure, pellet manufacturing in iron ore–ric..

Next Story
Building Material

IndiaAI, Gujarat Govt Host Regional Conclave Ahead of 2026 AI Summit

The IndiaAI Mission under the Ministry of Electronics and Information Technology, along with the Government of Gujarat and IIT Gandhinagar, convened a Regional Pre-Summit Event at Mahatma Mandir, Gandhinagar. The initiative is part of the build-up to the India–AI Impact Summit 2026, scheduled for 15–20 February 2026 at Bharat Mandapam, New Delhi. The conclave brought together senior policymakers, technology leaders, researchers and industry practitioners to examine how AI can accelerate economic, digital and social transformation across sectors. The programme focused on the overarching th..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Open In App